Compare Bristol-Myers Squibb Co (BMY) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wayfair Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.39 (market cap $116.30B), while Wayfair Inc trades at $92.5 (market cap $11.71B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.9× Wayfair Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| BMY | W | |
|---|---|---|
Market Cap | $116.30B | $11.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $119.05 |
52-Week Low | $42.60 | $53.37 |
Enterprise Value | $152.24B | $14.29B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Wayfair (W) trades at $86.37, down 3.21% today, with a bearish technical signal but strong analyst support. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company maintains revenue growth but operates at a net loss, with a negative net income margin of -2.41%. Positive sentiment is driven by expansion into brick-and-mortar stores and AI integration, as highlighted by Bloomberg on July 8, 2026.
The outlook is cautiously optimistic due to a 51.78% buy rating from analysts and a consensus price target of $92.64, offering potential upside. However, risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and competitive e-commerce pressures. Investors should weigh growth initiatives against financial sustainability amid macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
